We look forward to expanding our brand domestically in the US as well as globally
Nicholasville, Kentucky (PRWEB) January 06, 2015
MediVet America, the catalyst of the MediVet brand as the world’s leader in Veterinary regenerative medicine will announce on Jan 6, 2015 a change in name to MediVet Biologics. The new brand includes a new logo, company mission and customer materials. A new website will also launch today, improving users online experience. The rebranding reflects the many recent changes the company has undergone globally uniting the Veterinary holdings of Medical Australia (MLA:ASX) which include MediVet America, TutaVet & MediVet Pty Ltd. The rebranding will also serve to better define the products and services offered by MediVet for the large and small animal market as well as its vision for the future.
MediVet serves an international progressive network of thousands of veterinarians with products such as Platelet Rich Plasma, Adipose Derived Stem Cell Treatments, and Autologous Conditioned Serum (IRAP ACS). The company has several Research and Development projects in the pipeline including other breakthrough biologic therapies coming to market in 2015.
In an effort to continue the advancement of the animal regenerative medicine space and provide the most, efficacious, and widely used provider of these therapies, MediVet Biologics continues to invest in the research and validation of the science. As of January 6th, 2015 the company has several ongoing R&D studies/projects at, The University of Kentucky, College of Medicine, University of Georgia College of Veterinary Medicine, & Kansas State University.
“Our in-clinic adipose derived stem cell treatments have been very well received by the North American Veterinary market and have allowed us to assist animals as well as add brick and mortar value to Veterinarian practices in a shifting and dynamic market. We look forward to expanding our brand domestically in the US as well as globally,” Jeremy Delk, C.E.O. MediVet Biologics.
About MediVet Biologics
MediVet Biologics headquartered just outside Lexington, Kentucky and Sydney, Australia. Medivet Biologics is a subsidiary of Medical Australia (MLA: ASX). MediVet Biologics has global reach including established partners in 26 countries around the world as well as strong market positioning in North America. The company provides novel treatment options based in science to the Veterinary market as well as provide unique customer specific service plans to ensure implementation and growth of its progressive products and services.
Medivet Biologics' mission is to set standards of excellence for providing biologic solutions to the veterinary market. Our company’s success, which is characterized by responsiveness and clinical excellence, has been founded on our dedication and quality innovative technologies. Veterinarians and pet owners trust MediVet Biologics to provide the quality care they expect and deserve. By providing services as though each pet were a member of our family, MediVet Biologics strives to be the preferred provider of Veterinary Regenerative Medicine products, equipment and services.